Pharmaceutical Executive
Outlining one country’s unique price-setting model for novel drugs-and the resulting pre-launch strategies for manufacturers.
Rafael Alencar
Advertisement
Articles by Rafael Alencar
Advertisement
Latest Updated Articles
CMED: The ‘Curupira’ of Brazil’s Pharma MarketFebruary 21st 2017
Advertisement
Advertisement
Trending on PharmExec
1
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
2
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
3
Pharmaceutical Executive Daily: Gilead Enters $1.87 Billion Collaboration and License Agreement with Vir Biotechnology
4
FDA Launches Rare Disease Framework Initiative
5